Healthcare
Live Price
Offline$74.96
+3.19% today
1Y Change
+44.10%
Window
Jun 30, 2025 → Jun 26, 2026
Coverage: 249 bars · Jun 30, 2025 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Halozyme Therapeutics, Inc. (HALO) is a Healthcare stock with a market cap of $7.54B and listed on NASDAQ. The stock last traded around $74.96 and up 44.1% across the available one-year price window (Jun 30, 2025 → Jun 26, 2026). Baseline metrics include revenue growth of +37.6%, EPS growth of -24.6%, a dividend yield of 0.0%. What stands out right now is revenue +37.6%, EPS -24.6%, free cash flow +37.6% with operating margin 58.4% and ROIC 23.6%. Valuation sits in the middle of the pack at P/E 23.6 and price/sales 5.4. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines HALO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
HALO is 26.11 pts ahead over the shared 1Y window.
HALO had 15.00 pts deeper max drawdown than SPY.
HALO beat SPY in 1 of 2 calendar years shown and trailed in 1.
HALO
+44.10%
Normalized return
SPY
+17.99%
S&P 500
Excess Return
+26.11 pts
Relative to SPY
HALO Max Drawdown
-24.13%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for HALO and SPY.
| Year | HALO | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +6.61% | +6.71% | -0.09 pts | SPY |
| 2025 | +30.14% | +11.19% | +18.95 pts | HALO |
Powered by FMP stock_dividend. Includes historical ex-dates, pay dates, and payout amounts.
Dividend Yield
No active yield
Trailing 12M Payout
$0.00
Last Payout
—
Next Step
Dividend yield means more when it is matched with payout durability, earnings quality, and sector context.